Table IV.
General characteristics of PD combined with MG.
| Characteristic | Concomitant PD and MG (n=47) | PrePD-MG (n=30) | PreMG-PD (n=12) | CoPD-MG (n=5) | P-valuea |
|---|---|---|---|---|---|
| Mean ± SD PD-onset age, years | 68.76±9.44 | 66.60±9.81 | 72.58±6.72 | 73.50±10.25 | 0.061 |
| Mean ± SD MG-onset age, years | 69.67±10.25 | 71.91±9.92 | 64.25±9.78 | - | 0.030b |
| Sex, M/F | 35/12 | 23/7 | 8/4 | 4/1 | 0.505 |
| History diseases, % | |||||
| Hypertension | 21.43 | 35.71 | 0 | 20.00 | 0.039b |
| Diabetes mellitus | 10.71 | 14.29 | 0 | 20.00 | 0.360 |
| Other immune diseases, % | |||||
| Thyroid disease | 42.86 | 21.43 | 66.67 | 60.00 | 0.042b |
| Neuropathy | 25.00 | 7.14 | 55.56 | 20.00 | 0.018b |
| RA | 3.58 | 7.14 | 0 | 0 | 0.609 |
| Crohn's disease | 3.58 | 7.14 | 0 | 0 | 0.609 |
| Myopathy | 3.58 | 7.14 | 0 | 0 | 0.609 |
| Median disease interval, years | 5 | 5 | 5 | - | |
| PD symptoms, % | |||||
| R | 88.00 | 90.00 | 75.00 | 100.00 | 0.437 |
| RT | 64.00 | 70.00 | 50.00 | 0 | 0.407 |
| BK | 64.00 | 65.00 | 50.00 | 100.00 | 0.486 |
| Hm | 32.00 | 35.00 | 0 | 100.00 | 0.224 |
| PD treatment, % | |||||
| Levodopa | 85.71 | 93.75 | 50.00 | 100.00 | 0.088 |
| THP | 19.05 | 25.00 | 0 | 0 | 0.376 |
| DA | 14.29 | 18.75 | 0 | 0 | 0.491 |
| MAO-B | 19.05 | 25.00 | 0 | 0 | 0.376 |
| COMT | 19.05 | 25.00 | 0 | 0 | 0.376 |
| Amantadine | 9.52 | 12.50 | 0 | 0 | 0.632 |
| MG symptoms, % | |||||
| Ocular symptoms | 69.57 | 62.07 | 83.33 | 100.00 | 0.138 |
| Head drop | 54.54 | 71.43 | 25.00 | 0 | 0.013b |
| Dysphagia | 55.32 | 54.84 | 50.00 | 75.00 | 0.521 |
| Dysarthria | 38.30 | 35.48 | 41.67 | 50.00 | 0.485 |
| Limb weakness | 36.36 | 32.14 | 50.00 | 100.00 | 0.427 |
| MG-antibodies, % | |||||
| AChR-Ab | 77.50 | 76.92 | 77.78 | 80.00 | 0.670 |
| MuSK-Ab | 5.00 | 3.85 | 0 | 20.00 | 0.743 |
| MG-treatment, % | |||||
| Pyd | 96.88 | 96.30 | 100.00 | 100.00 | 0.871 |
| CS | 40.63 | 44.44 | 0 | 100.00 | 0.123 |
| IVIG | 12.8 | 18.52 | 0 | 100.00 | 0.475 |
| AZA | 31.25 | 29.63 | 25.00 | 100.00 | 0.673 |
aP-value, PrePD-MG vs. PreMG-PD.
bSignificant P-values (P<0.05). P-values were calculated using independent t-tests or Fisher's exact test. F, female; M, male; PD, Parkinson's disease; MG, myasthenia gravis; Hm, hypomimia; R, rigidity; RT, resting tremor; BK, bradykinesia; RA, rheumatoid arthritis; THP, trihexyphenidyl; DA, dopamine receptor agonist; MAO-B, monoamine oxidase-B inhibitor; COMT, catechol-O-methyltransferase inhibitor; AChR, acetylcholine receptor; MuSK, muscle-specific kinase; AZA, azathioprine; CS, prednisone/methylprednisolone; Pyd, pyridostigmine; IVIG, intravenous immunoglobulin.